Рет қаралды 1,514
The 90-minute national webinar featured guest presentations on emerging gene therapies from Opus, a potential anti-oxidative treatment from Nacuity, and a promising cell-based treatment from OkuloVision. The panel answered questions from the audience on a wide range of research, clinical, and therapy development topics.
Featured Speakers:
- Jami R. Kern, MBA PhD, Nacuity Pharmaceuticals, SVP, Chief Clinical Officer
- Marie Csete, MD, PhD, Chief Executive Officer, OkuloVision
- Erin O'Neil, MD, VP of Clinical Development , Opus Genetics
- Claire Gelfman, PhD, Chief Scientific Officer, Foundation Fighting Blindness
- Ben Shaberman, VP, Science Communications, Foundation Fighting Blindness